Journal of Environmental Protection and Ecology 25, No 6, 2109–2118 (2024)

Computer application

BIOMEDICAL IMAGES UTILISED TO ANALYSE THE EXPRESSION OF DEATH RECEPTOR LIGANDS

GANESH KHEKARE[a]*, P. KALIYAMOORTHI[b], SWAPNIL PARIKH[c], K. B. V. BRAHMA RAO[d], SHIRISH DATTATREYA KULKARNI[e], URVASHI KHEKARE[f], S. KARTHICK[g], A. RAJARAM[h]

[a]*School of Computer Science and Engineering, Vellore Institute of Technology, 632 014 Vellore, Tamil Nadu, India*
E-mail: *ganeshkhekare05@gmail.com*
[b]*Deparment of Computer Science and Engineering, Madanapalle Institute of Technology and Science, 517 325 Andhra Pradesh, India*
[c]*Deparment of Computer Science and Engineering, Parul Institute of Engineering and Technology, PostLimda, 391 760 Gujarat, India*
[d]*Deparment of Computer Science and Engineering, Koneru Lakshmaiah Education Foundation, 522 302 Andhra Pradesh, India*
[e]*Faculty of Law, Symbiosis International (Deemed University) (SIU), Vimannagar, 411 014 Pune, Maharashtra, India.*
[f]*School of Mechanical Engineering, Vellore Institute of Technology, 632 014 Vellore, Tamil Nadu 4, India*
[g]*Deparment of Electronics and Communication Engineering, Erode Sengunthar Engineering College, 638 057 Erode, Tamil Nadu, India*
[h]*Department of Electronics and Communication Engineering, E.G.S. Pillay Engineering College, 611 002Nagapattinam, Tamil Nadu, India*

Abstract. The expression of death receptor ligands in biological samples can be analysed with the use of biomedical imaging. These pictures, which were produced by a variety of imaging methods including immunohistochemistry, immunofluorescence, and microscopy, let scientists see how death receptor ligands are distributed geographically and how abundantly they are within organisms. Biomedical images are a significant source of data for quantitative research. Quantitative parameters including signal intensity, spatial distribution, and death receptor ligand localisation patterns can be extracted using image processing methods and machine learning approaches. In this work, present a unique method, DeepVisBioNet, to evaluate the expression of death receptor ligands in biomedical images. The DeepVisBioNet system precisely detects and measures the expression levels of death receptor ligands in cellular samples by fusing deep learning techniques with specialised biomedical image processing methodologies. DeepVisBioNet facilitates the automated study of complicated biological pictures by utilising convolutional neural networks and sophisticated image processing techniques. This allows for the quick and precise identification of regions that contain death receptor ligands. DeepVisBioNet outperforms conventional techniques in terms of accuracy and efficiency

* For correspondence.

after undergoing thorough validation tests on a variety of biomedical image datasets. The suggested method has a lot of potential to cellular signalling pathways and may have important ramifications for drug development and biological studies that focus on death receptor-mediated signalling pathways.

Keywords: death receptor ligands, biomedical imaging, image processing, machine learning, DeepVisBioNet, deep learning, convolutional neural network.

AIMS AND BACKGROUND

Programmed cell death receptor 1 (PD-1) is a critical immune checkpoint protein expressed on the surface of certain immune cells, particularly T cells[1]. Restoring T-cell proliferation and cytokine production is crucial for mounting an effective immune response against the tumor. With the PD-L1/PD-1 pathway blocked, T cells are no longer suppressed, allowing them to proliferate, produce cytokines, and exert cytotoxic effects on tumor cells. This immune activation leads to tumor cell death and, in some cases, tumor regression[2]. Ligand-based cheminformatics methods offer an alternative approach for identifying new drug-target interactions without relying on target protein-derived information. Instead of directly docking ligands into target protein structures, these methods focus on analysing the properties and characteristics of ligands themselves, such as their chemical structure, physicochemical properties, and biological activities[3]. Red and green fluorescence signals were chosen by manual thresholding, and then Image was used to compute Mender's coefficients (M1). For analysis, the final mean values along with the standard error of the mean (SEM) were presented as a histogram[4]. Among the most studied and well-known inhibitory checkpoint mechanisms in immunology are those involving cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), programmed cell death receptor-1 (PD-1), and programmed cell death ligand-1 (PD-L1) (Ref. 5). Treatment resistance and unintentional immunogenicity are two of the difficulties that have surfaced despite the increasing experience with using immunotherapy drugs in clinical practice[6]. Cell viability was evaluated in NK-92 cells grown with either anti-human CD95 or mouse IgM isotype control for cytotoxicity experiments. Effects of the therapies could be compared since control cells received the same treatments in parallel without the addition of an antibody[7]. After the mice were sacrificed, a variety of tissues were taken from them, including hearts, livers, spleens, kidneys, and lungs, as well as xenograft tumors. Dehydrated using xylene and an ethanol gradient, the fixed tissues was embedded in paraffin. After the tissues had been fixed in paraffin, sections were cut out and stained with hematoxylin and eosin (H&E) for microscopic inspection[8]. Immunotherapy has completely changed the way that cancer is treated, but a large percentage of people do not respond to it. This is frequently because tumor cells use immunosuppressive ligands to avoid being seen by the immune system[9]. A common feature of many tumors is the presence of death receptors, and activating these receptors offers a viable path for targeted cancer therapy approaches[10]. Extensive experiments on

several biomedical image datasets have verified the higher accuracy and efficiency of DeepVisBioNet.

EXPERIMENTAL

Various imaging modalities make it easier to analyse death receptor ligand expression in biological samples, which is essential for comprehending cellular signalling cascades. Here, we present a novel method called DeepVisBioNet, which precisely measures the amounts of death receptor ligand expression by combining deep learning with specialised biomedical image processing. DeepVisBioNet is an automated system that analyses biological images using convolutional neural networks and sophisticated image processing techniques to identify regions harbouring death receptor ligands quickly and accurately. DeepVisBioNet surpasses traditional methods in accuracy and efficiency after extensive validation on a variety of biomedical image datasets. This novel strategy could have ramifications for drug development and scientific research by deepening knowledge of cellular signalling pathways, especially those regulated by death receptors.



Fig. 1. Block diagram for death receptor ligands

Death receptor ligands in biological samples are analysed using biomedical imaging by DeepVisBioNet, as demonstrated by the streamlined workflow block diagram shown in Fig. 1. After pre-processing biomedical images to improve their quality, sophisticated methods such as CNNs are used to extract features from the images. The deep learning model is then enhanced by specific biomedical image

processing techniques to detect and quantify the amounts of death receptor ligand expression. Complete insights into death receptor ligand expression patterns are made possible by the output, which includes locations that have been identified and accurately quantified. Strict validation and performance assessment guarantee the accuracy and efficacy of the technology, highlighting its potential to propel drug development and biological research aimed at death receptor-mediated signalling pathways.

INPUT BIOMEDICAL IMAGES

The main source of data for the study is biomedical pictures obtained through various imaging techniques such immunohistochemistry, immunofluorescence, and microscopy. The spatial distribution and relative abundance of death receptor ligands in biological samples are shown visually in these photos. Tissue sections can be stained in depth using immunohistochemistry, fluorescently labeled ligands can be seen using immunofluorescence, and careful analysis can be done with high-resolution images obtained by microscopy[11]. When combined, these imaging techniques provide crucial information about how death receptor ligands function in biological processes and cellular signalling cascades.

PRE-PROCESSING

The pre-processing module is crucial for helping to sharpen the input images before analysis. At this point, a number of pre-processing methods are applied to enhance the image quality and remove unwanted artifacts. For example, picture enhancement techniques sharpen edges and boost contrast to make minute details easier to notice, while noise reduction techniques limit random variations that could obscure key traits. Moreover, normalisation techniques ensure uniformity in image intensity levels across multiple samples, hence facilitating comparative analysis. By using this technique for picture preparation, the pre-processing module maximises the suitability of the images for additional analysis, allowing for more accurate and reliable data interpretation:

Noise reduction:

$$G(x, y) = 1/(2\pi\sigma^2) \times \exp\left(-(x^2 + y^2)/(2\sigma)\right) \times I(x, y). \quad (1)$$

Image enhancement:

$$\text{Output}(i, j) = (\text{CDF}(\text{Input}(i, j)) - \min \text{CDF})/(M \times N - \min \text{CDF}) \quad (2)$$

$$\text{Normalised}(i, j) = (\text{Original}(i, j) - \min)/(\max - \min). \quad (3)$$

The pre-processing module makes the input photos more suited for further analysis by using these formulas, which makes it easier to analyses the data with greater accuracy and dependability. While image enhancement techniques sharpen edges and increase contrast to make small details easier to see, noise reduction

techniques help to reduce random changes that might mask important features[12]. Furthermore, normalisation methods guarantee consistency in the levels of picture intensity in many samples, which facilitates comparison analysis. Pre-processing the images to standardise them will let the analysis that follows be carried out more precisely and provide more meaningful insights into the location and abundance of death receptor ligands in biological samples.

FEATURE EXTRACTION MODULE

Important properties linked to death receptor ligand expression are captured by extracting essential features from the pre-processed pictures using the feature extraction module. Boundaries between areas of interest can be defined by methods like edge detection algorithms, which detect sharp variations in pixel intensity. In order to identify patterns suggestive of death receptor ligand distribution and organisation within the sample, texture analysis methods examine the spatial arrangement of pixel intensities[13]. Furthermore, the images are automatically trained and complicated hierarchical features are extracted by convolutional neural networks (CNNs), which make it possible to identify delicate and complex patterns linked to the expression of death receptor ligands.

$$(f \times g)(i, j) = \sum_{m,n} (m, n) \times g(i - m, j - n) \tag{4}$$

$$x_i = \exp(x_i) / \sum_j \exp(x_j). \tag{5}$$

Through the integration of these many methodologies, the feature extraction module improves the capacity to identify and measure the expression levels of death receptor ligands in biomedical pictures, thereby enabling thorough examination and comprehension of cellular signalling pathways.

DEEP LEARNING MODEL

Convolutional neural network (CNN) architecture is used by DeepVisBioNet for both learning and inference tasks. This CNN model can identify complex patterns and features linked to death receptor ligand expression since it has been painstakingly trained using annotated biological images. The model gains the ability to automatically identify and quantify the expression levels of death receptor ligands in cellular samples during training[14–16]. The CNN gathers pertinent information from the input images and uses the hierarchical layers of convolutional operations, pooling, and fully connected layers to turn the information into precise predictions[17]. DeepVisBioNet's CNN delivers excellent sensitivity and specificity in identifying regions containing death receptor ligands through this process of learning from annotated data, enabling accurate quantification and analysis.

$$f(x) = \sigma(W x + b). \tag{6}$$

This strong deep learning methodology improves the ability to interpret intricate biological images, providing insightful information about cellular signalling networks and supporting drug discovery and biological research on death receptor-mediated signalling pathways.

BIOMEDICAL IMAGE PROCESSING TECHNIQUES

Accurate analysis of death receptor ligands depends critically on specialised image processing methods designed for biological imaging. Through noise reduction and boundary enhancement, morphological processes fine-tune cellular structures, guaranteeing accurate localisation and measurement of ligand expression levels. Images are divided into discrete parts by segmentation algorithms, which make it easier to precisely identify and measure the expression of death receptor ligand in specific cells or structures. DeepVisBioNet automates the detection and measurement of ligand expression with remarkable efficiency and accuracy by blending these methods with ease.

$$(1 - B)(x, y) = \min_{(i,j)\in B} \{I(X - I,\ Y - J) - B(I, J)\}. \tag{7}$$

This thorough method holds great promise for drug development and biological research centred on death receptor-mediated signalling pathways, in addition to advancing understanding of cellular signalling pathways. The ability of DeepVisBioNet to precisely quantify ligand expression provides new opportunities for therapeutic investigation and clarifies the complex roles that death receptors play in a range of physiological and pathological processes.

ANALYSES

The products of DeepVisBioNet's study include quantitative assessments of signal strength, spatial distribution, and localisation patterns, along with locations that have been identified as holding death receptor ligands. The cellular samples' death receptor ligand expression profile can be better understood with the help of these comprehensive insights. DeepVisBioNet enables detailed analysis and interpretation of death receptor ligand expression by accurately identifying regions of interest and providing quantitative measures. It is possible to make comparisons between various samples and situations using this information, which also clarifies the geographic distribution and quantity of death receptor ligands. In the end, DeepVisBioNet's output improves understanding of cellular signalling pathways and advances the investigation of possible treatment approaches that target signalling pathways controlled by death receptors.

RESULTS AND DISCUSSION

The results of this investigation highlight how crucial it is to take experimental settings into account when analysing death receptor ligands. The fluctuations in expression levels that have been observed underscore the fluidity of cellular signalling pathways and the intricate interaction of variables that govern death receptor-mediated signalling. These findings also have important ramifications for comprehension of how cells react to different stimuli and for the creation of tailored treatments. This discovery broadens understanding of cellular biology by clarifying the regulation of death receptor-mediated signalling pathways. It may also help design new therapeutic approaches that specifically target these pathways.

Evaluation metrics provide quantitative measurements to evaluate the performance of models in classification, regression, or clustering tasks. Examples of these metrics include accuracy, recall, and MCC. These indicators offer insights into strengths and weaknesses and help with model selection, parameter adjustment, and overall effectiveness assessment[18–22]. The goals and specifications of the task determine which metrics are appropriate.

$$\text{Accuracy} = (TP + TN)/(TP + TN + FP + FN) \tag{8}$$

$$\text{Recall} = TP/(TP + FN) \tag{9}$$

$$\text{MCC} = \frac{TP\ XTN - FP\ XFN}{((TP + FP)(TP + FN)(TN + FP)(TN + FN))^{1/2}}. \tag{10}$$

Table 1 shows a comparison of the accuracy, recall, and Matthew's correlation coefficient (MCC) between the DeepVisBioNet training set and the current approaches. The suggested deep learning-based strategy is called DeepVisBioNet, while the current techniques are Decision Trees (DT), Extra Trees (ET), Random Forest (RF), Gradient Boosting (GB), and Extreme Gradient Boosting (XGB).

Table 1. Comparison between existing and DeepVis BioNet training set

Method	Existing					Proposed
	DT	ET	RF	GB	XGB	DeepVisBio Net
Accuracy	0.935	0.935	0.935	0.897	0.862	0.958
Recall	0.935	0.935	0.935	0.897	0.862	0.958
MCC	0.728	0.757	0.743	0.737	0.738	0.865

The performance metrics of the DeepVisBioNet training set and the current approaches are comprehensively compared in Fig. 2. In particular, DeepVisBioNet surpasses the best accuracy of 0.935 achieved by current approaches, with an accuracy of 0.958. In a similar vein, DeepVisBioNet performs better in recall, demonstrating its capacity to catch true positives, with a value of 0.958 as opposed

to the greatest recall value of 0.935 attained by current techniques. Additionally, DeepVisBioNet has a markedly better MCC of 0.865, demonstrating a high degree of agreement between the predicted and actual classifications. By comparison, current techniques produce MCC values between 0.728 and 0.743, which emphasises DeepVisBioNet's improved predictive capability.



Fig. 2. Comparison between existing and DeepVisBioNet training

Table 2 compares the effectiveness of the proposed DeepVisBioNet with the approaches that are currently in use on the testing set. The comparison is based on three metrics: MCC, accuracy, and recall. DeepVisBioNet is the suggested deep learning-based technique, whereas the current approaches include Decision Trees (DT), Extra Trees (ET), Random Forest (RF), Gradient Boosting (GB), and Extreme Gradient Boosting (XGB).

Table 2. Comparison between existing and DeepVis BioNet testing

Method	Existing					Proposed
	DT	ET	RF	GB	XGB	DeepVisBio-Net
Accuracy	0.727	0.756	0.742	0.736	0.729	0.843
Recall	0.728	0.757	0.743	0.737	0.730	0.813
MCC	0.641	0.678	0.659	0.651	0.642	0.756

The comparison of DeepVisBioNet with existing approaches on the testing set is shown in Fig. 3, with particular attention paid to performance parameters like as MCC, accuracy, and recall. DeepVisBioNet routinely beats the current techniques in every evaluation metric. Its exceptional performance in successfully identifying data on the testing set is demonstrated by the best accuracy, recall, and MCC values that it achieves in comparison to other approaches. In particular, DeepVisBioNet surpasses the best accuracy of 0.756 achieved by current approaches, with an accuracy of 0.843. Comparing DeepVisBioNet to other approaches, it also shows greater recall and MCC values, suggesting that it can capture true positives and produce good agreement between projected and actual classifications.



Fig. 3. Comparison between existing and DeepVisBioNet testing

CONCLUSIONS

To sum up, DeepVisBioNet is a ground-breaking tool that is transforming the study of death receptor ligands in biological pictures. Its precise detection and measurement of these ligands' expression levels in cellular samples represents a major advancement due to its integration of deep learning with specialised image processing techniques. DeepVisBioNet has proven to be more precise and efficient than traditional methods through rigorous validation across a variety of datasets. This has given researchers a strong platform to explore the complex spatial distribution and abundance of death receptor ligands within organisms. Future developments in DeepVisBioNet's capabilities could potentially expand its use to more biological research and speed up the creation of new drugs that target death receptor-mediated signalling pathways. The ability of DeepVisBioNet to decipher the intricate workings of cellular signalling networks highlights the critical role that it has played in reshaping the field of cellular biology and biomedical imaging research, opening the door to ground-breaking findings and novel therapeutic approaches.

REFERENCES

1. A. L. ROSSI, M. LE, C. S. CHUNG, Y. CHEN, E. A. FALLON et al.: A novel Role for Programmed Cell Death Receptor Ligand 2 in Sepsis-induced Hepatic Dysfunction. Am J Physiol Gastrointest Liver Physiol, **316** (1), G106 (2019).
2. S. KUTTAPPAN, R. BHOWMIK, C. GOPI MOHAN: Probing the Origins of Programmed Death Ligand-1 Inhibition by Implementing Machine Learning-assisted Sequential Virtual Screening Techniques. Mol Divers, 1 (2023).
3. N. T. ISSA, V. STATHIAS, S. SCHÜRER, S. DAKSHANAMURTHY: Machine and Deep Learning Approaches for Cancer Drug Repurposing. Semin Cancer Biol, **68**, 132 (2021).
4. A. MONDAL, R. Ne MOYER, M. VORA, L. NAPOLI, Z. SYED et al.: Bone Morphogenetic Protein Receptor 2 Inhibition Destabilizes Microtubules Promoting the Activation of Lysosomes and Cell Death of Lung Cancer Cells. Cell Commun Signal, **19**, 1 (2021).
5. J. A. MARIN-ACEVEDO, B. DHOLARIA, A. E. SOYANO, K. L. KNUTSON, S. CHUMSRI, Y. LOU: Next Generation of Immune Checkpoint Therapy in Cancer: New Developments and Challenges. J Hematol Oncol, **11**, 1 (2018).

6. Y. K. CHAE, A. ARYA, W. IAMS, M. R. CRUZ, S. CHANDRA et al.: Current Landscape and Future of Dual Anti-CTLA4 and PD-1/PD-L1 Blockade Immunotherapy in Cancer; Lessons Learned from Clinical Trials with Melanoma and Non-small Cell Lung Cancer (NSCLC). Journal for Immunotherapy of Cancer (JITC), **6**, 1 (2018).
7. L. NAVARRETE-GALVAN, M. GUGLIELMO, J. CRUZ AMAYA, J. SMITH-GAGEN, V. C. LOMBARDI et al.: Optimizing NK-92 Serial Killers: Gamma Irradiation, CD95/Fas-ligation, and NK or LAK Attack Limit Cytotoxic Efficacy. J Transl Med, **20** (1), 151 (2022).
8. Y. WANG, L. ZHANG, G. ZHAO, Y. ZHANG, F. ZHAN et al.: Homologous Targeting Nanoparticles for Enhanced PDT against Osteosarcoma HOS Cells and the Related Molecular Mechanisms. J Nanobiotechnol, **20** (1), 83 (2022).
9. D. H. LEE, H. AHN, H. I. SIM, E. CHOI, S. CHOI et al.: A CRISPR Activation Screen Identifies MUC-21 as Critical for Resistance to NK and T Cell-mediated Cytotoxicity. J Exp Clin Cancer Res, **42** (1), 272 (2023).
10. F. GALLI, J. V. AGUILERA, B. PALERMO, S. N. MARKOVIC, P. NISTICÒ, A.SIGNORE: Relevance of Immune Cell and Tumor Microenvironment Imaging in the New Era of Immunotherapy. J Exp Clin Cancer Res, **39**, 1 (2020).
11. J. J. SAHAYARAYAN, K. S. RAJAN, R. VIDHYAVATHI, M. NACHIAPPAN, D. PRABHU et al.: In-silico Protein-Ligand Docking Studies against the Estrogen Protein of Breast Cancer Using Pharmacophore Based Virtual Screening Approaches. Saudi J Biol Sci, **28** (1), 400 (2021).
12. M. ZHANG, X. LIU, F. WEN, Q. WU, K. ZHOU et al.: First-line Cemiplimab versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer Patients with at Least 50% Programmed Cell Death Receptor Ligand-1 Positivity: Analysis of Cost-Effectiveness. Clin Oncol, **34** (3), e123 (2022).
13. D. D. NGUYEN, Z. CANG, K. WU, M. WANG, Y. CAO, G. W. WEI: Mathematical Deep Learning for Pose and Binding Affinity Prediction and Ranking in D3R Grand Challenges. J Comput Aided Mol Des, **33**, 71 (2019).
14. W. XIE, Z. JIANG, X. ZHOU, X. ZHANG, M. ZHANG et al.: Quantitative Radiological Features and Deep Learning for the Non-invasive Evaluation of Programmed Death Ligand 1 Expression Levels in Gastric Cancer Patients: a Digital Biopsy Study. Acad Radiol, **30** (7), 1317 (2023).
15. D. SIEGMUND, P. HADWIGER, K. PFIZENMAIER, H. P. VORNLOCHER, H. WAJANT: Selective Inhibition of FLICE-like Inhibitory Protein (FLIP) Expression with Small Interfering RNA Oligonucleotides (siRNAs) Is Sufficient to Sensitize Tumor Cells for TRAIL-induced Apoptosis. Mol Med, **8**, 725 (2002).
16. N. POLOJU, A. RAJARAM: Transformation with Yolo Tiny Network Architecture for Multimodal Fusion in Lung Disease Classification. Cybern Systems, 1 (2024).
17. A. A. PRAKASH, T. THULASIMANI, S. R. PAWAR et al.: Environmental Monitoring Using WSNS for Sustainable Pest and Disease Control in Corn Production. J Environ Prot Ecol, **25** (1), 257 (2024).
18. S. GUPTA, N. PATEL, A. KUMAR et al.: Adaptive Fuzzy Convolutional Neural Network for Medical Image Classification. J Intell Fuzzy Syst, (Preprint), 1–17 (2023).
19. R. K. GANIYA, D. VEERAIAH, V. N. THATHA et al.: Revolutionizing Vascular Health through the Temporal Convolutional Transformer for Drug Screening and Model Evolution. Biomed Signal Process Control, **95**, 106390 (2024).
20. P. A. BABU, A. K. RAI, J. V. N RAMESH et al.: An Explainable Deep Learning Approach for Oral Cancer Detection. J Electr Eng Technol, **19** (3), 1837 (2024).
21. A. KARTHIK, S. S. AALAM, M. SIVAKUMAR et al.: Improving Brain Tumor Treatment with Better Imaging and Real-time Therapy Using Quantum Dots. Biomed Signal Process Control, **95**, 06286 (2024).
22. G. SUCHARITHA, V. SANKARDASS, R. RANI, N. BHAT, A. RAJARAM: Deep Learning Aided Prostate Cancer Detection for Early Diagnosis and Treatment Using MR with TRUS Images. J Intell Fuzzy Syst, **46** (2), 3395 (2024).

Received 18 July 2024
Accepted 9 August 2024